Newsroom | 49271 results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15. Since 2022, SonoThera has developed and established its proprietary RIPPLE™ technology and optimized it across multiple non-human pri...

BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting and reprogramming activated cells in the retina, today announced the appointment of George Montgomery as Executive Chairman, effective immediately. Mr. Montgomery brings over three decades of experience as an investor (private equity and venture capital), a start-up entr...

AUSTIN, Texas--(BUSINESS WIRE)--Surf Therapeutics, a clinical-stage neuro-immunomodulation company developing non-invasive ultrasound therapy for chronic inflammatory diseases, is announcing the start of an Early Feasibility Study evaluating its investigational ultrasound device in people living with rheumatoid arthritis. The study is designed to assess a non-invasive approach to activate a neural pathway that triggers a robust anti-inflammatory response, without the need for drugs, surgery, or...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today provided an update on the significant progress made during 2025 with its Dravet syndrome candidate, ETX101, including an overview of the positive interim Phase 1/2 clinical results announced last month, establishment of GMP manufacturing capabilities to support its pipeline of gene therapies, and progres...

LINKÖPING, Sweden--(BUSINESS WIRE)--AMRA Medical Introduces AMRA® BCP Scan in the Netherlands Through a Strategic Partnership with Prescan, a National Preventative Health Leader...

BOSTON--(BUSINESS WIRE)--Etiometry, a leader in AI-driven clinical intelligence, celebrates a year of significant achievements in 2025 and announces its vision to continue transforming critical care in the year ahead. In 2025, the company unveiled significant platform advancements, grew its number of hospital installations, secured its 10th FDA clearance, won a prestigious award, and showcased its clinical intelligence platform through numerous studies. Additionally, Etiometry continued focus o...

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property (“IP”) portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company’s long-term value creation and development strategy. In early Q3 2025, Oncolytics filed a Track 1 prioritized examination patent application with the United States P...

PITTSBURGH--(BUSINESS WIRE)--RQM+, a leading global MedTech service provider (CRO), today announced that Ross D. Segan, M.D., MBA, FACS, has joined its board of directors. Dr. Segan is a physician–executive and MedTech strategist with senior leadership experience at the U.S. Food and Drug Administration (FDA), Johnson & Johnson, Olympus, Covidien, and Vensana Capital, and currently serves as CEO of Medical Scientific Advisors, LLC. “Dr. Segan’s leadership at the intersection of clinical pra...

AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for A2B543 for the treatment of germline heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors. A2B543 contains a membrane-tethered I...